5-HTP

5-HTP is a Specialty supplement available in 1 form.

Not all forms of 5-HTP are equal. The form you choose determines how much 5-HTP actually reaches your tissues, and the difference between the best and worst forms can be substantial. 5-HTP (5-hydroxytryptophan) is the direct metabolic precursor to serotonin, crossing the blood-brain barrier more readily than L-tryptophan and bypassing the rate-limiting tryptophan hydroxylase conversion step. Research suggests this S1-tier form supports healthy mood, sleep onset, and appetite regulation with efficient bioavailability.

5-HTP Preferred (Preferred Form) has a bioavailability rating of high absorption.

5-HTP (5-hydroxytryptophan) is the direct precursor to serotonin, crossing the blood-brain barrier more efficiently than L-tryptophan. Clinical research supports its use for mood support and sleep quality, with multiple trials demonstrating measurable increases in serotonin metabolites. It is derived from Griffonia simplicifolia seed extract.

Steady-state oral 5-HTP systemic availability ranged 47-84% (mean 69.2% ± 4.7 SEM) across 5 patients receiving a decarboxylase inhibitor; dose-independent linear pharmacokinetics; time to peak plasma concentration 1.8-3.3 hours. PMID: 6966118

In 5 healthy volunteers dosed IV and orally with carbidopa pretreatment, oral bioavailability was 48% ± 15 (SD); biological half-life 2.2-7.4 hours; plasma clearance 0.10-0.23 L/kg/hour. A separate 8-subject arm showed carbidopa pretreatment significantly increased the extent of absorption of unchanged 5-HTP. PMID: 6187038

Direct proportionality between plasma 5-HTP and lumbar cerebrospinal-fluid 5-HTP concentrations in patients on steady-state treatment; 19% of circulating 5-HTP bound to serum proteins; preliminary comparison suggests carbidopa is superior to benserazide as the co-administered decarboxylase inhibitor. PMID: 6182005

5-HTP is classified as Preferred Form by FormulaForge — our top recommendation for 5-HTP. It carries a bioavailability rating of high absorption, meaning more of the active compound reaches your tissues per dose unit compared to lower-rated forms.

When choosing a 5-HTP supplement, read the label for the specific form name — that is what determines how much you actually absorb. Preferred Forms have the strongest research-backed evidence for efficient absorption.

Other forms may be appropriate depending on individual goals, cost considerations, and your healthcare provider’s guidance. The best form for you depends on your specific health needs.

Individual dose requirements vary based on health goals, body weight, and existing nutrient intake. Your healthcare provider can help you determine an appropriate amount of 5-HTP for you.

Side Effects: Consult your healthcare provider regarding tolerability, particularly at higher doses.

These statements are based on structure/function research and have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before starting or changing a supplement regimen.

The following studies and findings inform FormulaForge classifications for 5-HTP:

Steady-state oral 5-HTP systemic availability ranged 47-84% (mean 69.2% ± 4.7 SEM) across 5 patients receiving a decarboxylase inhibitor; dose-independent linear pharmacokinetics; time to peak plasma concentration 1.8-3.3 hours. PMID: 6966118

In 5 healthy volunteers dosed IV and orally with carbidopa pretreatment, oral bioavailability was 48% ± 15 (SD); biological half-life 2.2-7.4 hours; plasma clearance 0.10-0.23 L/kg/hour. A separate 8-subject arm showed carbidopa pretreatment significantly increased the extent of absorption of unchanged 5-HTP. PMID: 6187038

Direct proportionality between plasma 5-HTP and lumbar cerebrospinal-fluid 5-HTP concentrations in patients on steady-state treatment; 19% of circulating 5-HTP bound to serum proteins; preliminary comparison suggests carbidopa is superior to benserazide as the co-administered decarboxylase inhibitor. PMID: 6182005